0001209191-20-054622.txt : 20201013
0001209191-20-054622.hdr.sgml : 20201013
20201013160447
ACCESSION NUMBER: 0001209191-20-054622
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201012
FILED AS OF DATE: 20201013
DATE AS OF CHANGE: 20201013
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRICE MICHAEL DENNIS
CENTRAL INDEX KEY: 0001247313
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38137
FILM NUMBER: 201236305
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001662524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472608175
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 22 BOSTON WHARF RD
STREET 2: 9TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-207-0202
MAIL ADDRESS:
STREET 1: 22 BOSTON WHARF RD
STREET 2: 9TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-12
1
0001662524
AKCEA THERAPEUTICS, INC.
AKCA
0001247313
PRICE MICHAEL DENNIS
C/O AKCEA THERAPEUTICS, INC.
22 BOSTON WHARF ROAD, 9TH FLOOR
BOSTON
MA
02210
0
1
0
0
Chief Financial Officer
Common Stock
2020-10-12
4
U
0
50000
18.15
D
0
D
Stock Option (right to buy)
14.78
2020-10-12
4
D
0
300000
3.37
D
2030-05-17
Common Stock
300000
0
D
This option, which provided that 1/4th of the shares would vest one year after May 18, 2020 and that 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $1,011,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
/s/ Joshua F. Patterson, Attorney-in-Fact
2020-10-12